Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the ...

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

“Pfizer appears cheap with a near 7% yield, but capital allocation constraints undermine its investment case. Nearly all of ...

The company expects to launch more than 20 pivotal late-stage trials this year.

Pfizer also releases positive top-line results from a trial for its injectable GLP-1 receptor agonist in adults with obesity.

Pfizer (PFE) delivered earnings and revenue surprises of +16.81% and +4.26%, respectively, for the quarter ended December ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

Pfizer shares fell 3.3% Tuesday on what some market watchers called underwhelming study results for an experimental weight-loss drug the drugmaker obtained after a contentious and costly bidding war ...

Thus far, Pfizer's obesity efforts have crashed and burned. Last year, the pharmaceutical giant threw in the towel on ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer reported strong mid-stage weight loss trial results for its monthly obesity drug and posted fourth-quarter earnings ...

Analysts expect Pfizer’s revenue to decrease approximately 5% to around $16.95 billion, while adjusted earnings per share are projected to fall 9.5% to 57 cents compared to 63 cents in the same period ...